Tenofovir ve entekavirin noninvaziv biyobelirteçler üzerindeki 5 yıllık değişimlerinin karşılaştırılması

Kronik karaciğer hastalıklarının morbidite ve mortalitesi karaciğer fibrozisinin derecesi ile yakından ilişikilidir. Karaciğer fibrozisinin artık geri dönüşlü olduğu ve tedavi ile geri döndürülebildiği bilinmektedir. Bu çalışmada, kronik hepatit B hastalarındaki fibrozisin gerilemesinde potent antivirallerin etkinliği non-invaziv testler üzerinden araştırılmış; şayet iyileşme yönünde etkinlikleri varsa aralarında bir farkın olup olmadığına bakılmıştır. Gereç ve Yöntem: Karaciğer biyopsisi yapılan kronik hepatit B hastalarının tıbbi kayıtları sistematik olarak incelendi ve uygunluk açısından tarandı. Potent antiviral tedavi başlanan ve 5 yıl boyunca alan naiv hastalar seçildi. Bu hastaların çalışılan non-invaziv biyobelirteçlerinin; aspartat aminotransferaz-alanin aminotransferaz oranı, yaş/trombosit indeksi, aspartat aminotransferaz/trombosit oran endeksi, fibrozis indeks-based 4, trombosit sayımı, ortalama trombosit hacmi başlangıç, 3. yıl ve 5. yıl değerleri karşılaştırıldı. Bulgular: Tenofovir ve entekavir alan hastalarda aspartat aminotransferaz/trombosit oran endeksi, aspartat aminotransferaz-alanin aminotransferaz oranı, yaş/trombosit indeksi, ortalama trombosit hacmi ve trombosit dağılımları açısından takip süresince istatistiksel olarak anlamlı bir fark vardı (Friedman p

Comparison of 5-year changes of tenofovir and entecavir on noninvasive markers

The morbidity and mortality of chronic liver diseases are closely linked to the degree of liver fibrosis. It is understood that liver fibrosis is now reversible and can be reversed with treatment. In this study, the efficacy of potent antivirals in the regression of liver fibrosis in chronic hepatitis B patients was investigated on noninvasive tests; moreover, it is examined if there is a disparity between them. Materials and Methods: Medical records of chronic hepatitis B patients who underwent liver biopsy were routinely checked and screened for compliance. Potent antiviral treatment was initiated in selected naive patients who were treated for 5 years. The noninvasive biomarkers (aspartate aminotransferase/alanine aminotransferase ratio, aspartate aminotransferase/platelet ratio index, age/platelet index, fibrosis index based four factor, platelet, mean platelet volume) of these patients were compared at baseline, third year, and fifth year. Results: There was a statistically significant difference in the distribution of aspartate aminotransferase/platelet ratio index, aspartate aminotransferase/ alanine aminotransferase ratio, age/platelet index, mean platelet volume, and platelet in patients treated with both tenofovir and entecavir during treatment period (Friedman p

___

  • 1. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85. Erratum in: J Hepatol 2013;58:201.
  • 2. Zani C, Pasquale L, Bressanelli M, et al. The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C. Dig Liver Dis 2011;43:653-8.
  • 3. Yalaki S, Yalçın MS, Zerman A. Malign karaciğer kitleleri, 127 olgunun retrospektif değerlendirilmesi. Van Tıp Derg 2018;25:17-21.
  • 4. Hammel P, Couvelard A, O’Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23.
  • 5. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
  • 6. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75.
  • 7. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007;5:921-31.
  • 8. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
  • 9. Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PloS One 2014;9:e98865.
  • 10. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012;23:247-52.
  • 11. Park JW, Kwak KM, Kim SE, et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol 2017;17:39.
  • 12. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44:1249-53.
  • 13. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997;4:199-208.
  • 14. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008;40:267-74.
  • 15. Sterling RK, Lissen E, Clumerk N, et al. Development of a simple noninvazive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
  • 16. WHO. Guidelines for the prevention, care and treatment of persons with Chronic Hepatitis B infection. Geneva: WHO; 2015.
  • 17. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase -to- platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-36.
  • 18. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20.
  • 19. Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009;29:409-15.
  • 20. Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010;30:546-53.
  • 21. Park SY, Kang KH, Park JH, et al. Clinical efficacy of AST/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis. Korean J Gastroenterol 2004;43:246-51.
  • 22. Karasu Z, Tekin F, Ersoz G, et al. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci 2007;52:1535-9.
  • 23. Pokora Rodak A, Kiciak S, Tomasiewicz K. Neutrophil-lymphocyte ratio and mean platelet volume as predictive factors for liver fibrosis and steatosis in patients with chronic hepatitis B. Ann Agric Environ Med 2018;25:690-2.
  • 24. Ceylan B, Fincanci M, Yardimci C, et al. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol 2013;25:606- 12.
  • 25. Basar Ö, Yımaz B, Ekiz F, et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013;37:152-8.
  • 26. Koksal AR, Alkim H, Boga S, et al. Effect of entecavir and tenofovir treatment on noninvasive fibrosis scores: Which one is better? Am J Ther 2016;23:e429-38.
  • 27. Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med 2018;18:273- 82.
Akademik Gastroenteroloji Dergisi-Cover
  • ISSN: 1303-6629
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2002
  • Yayıncı: Jülide Gülay Özler
Sayıdaki Diğer Makaleler

Endoskopik retrograd kolanjiyopankreatografinin endikasyonları, sonuçları ve komplikasyonları: Doğu Karadeniz’deki üçüncü basamak bir merkezin 3 yıllık verileri

Sami FİDAN, Arif COŞAR

Gastroskopik girişimlerde sedoanaljezi uygulanan anemik hastalarda entegre pulmoner indeks ve solunum komplikasyonlarındaki değeri

Hızır KAZDAL, Şule BATÇIK, Leyla KAZANCIOĞLU, İlkay BAHÇECİ, Remzi Adnan AKDOĞAN

Endoskopik retrograd kolanjiyopankreatografinin endikasyonları, sonuçları ve komplikasyonları: Doğu Karadeniz'deki üçüncü basamak bir merkezin 3 yıllık verileri

Sami FİDAN, Arif COŞAR

Dieulafoy lezyonu tanılı hastalarda endoskopik tedavi başarısı ve takip sonuçları

Göktuğ ŞİRİN, Ali Erkan DUMAN, Hasan YILMAZ, Sibel BALCI, Ayça EROĞLU HAKTANIR, Emrullah DENGEŞİK, Kenan ÖZENDİ, Altay ÇELEBİ, Sadettin HULAGU

20 mm’den büyük geniş sesil kolon poliplerinde soğuk snare ile parçalı EMR

Yücel ÜSTÜNDAĞ, İbrahim Halil DÜŞÜNCELİ

Kronik hepatit C tedavisinde ikinci kuşak direk etkili oral antivirallerin gerçek yaşam verileri: Tek merkez ve heterojen hasta grubu

Mustafa AKAR, Tevfik SOLAKOĞLU

Akut gastrointestinal sistem kanması: Endoskopi sonrası sırada ne var? Olgu sunumu

Feyzi BOSTAN, Halit KAYA, Ersin KAPAĞAN, Rıdvan YAVUZ, Ayhan Hilmi ÇEKİN

COVID-19’da gastrointestinal semptomlar ile hastalığın seyri ve prognozu arasında bir ilişki var mı? Tek merkezli pilot çalışma

Enver AVCI, İsa ARDAHANLI, Erkin ÖZTAŞ, Selçuk DİŞİBEYAZ

A rare cause of the chronic diarrhea in geriatric patients: Vitamin D deficiency

Orhan COŞKUN, Mustafa ÇAPRAZ, Mustafa KAPLAN

Sedasyon Uygulanan Gastroskopik Girişimlerde Aneminin Integrated Pulmonary Index (IPI ) Skoruna Etkisi

Hizir KAZDAL, Şule BATÇIK, Leyla KAZANCIOĞLU, İlkay BAHÇECİ, Remzi AKDOĞAN